Preliminary data show intracameral implant reduces IOP up to 9 months

SAN FRANCISCO — An intracameral travoprost implant reduced IOP for up to 9 months in preliminary results from a phase 1 study, according to a speaker here.
The open-label, proof-of-concept study included 20 subjects who received one of two formulations of OTX-TIC (travoprost implant, Ocular Therapeutix), administered via a single injection, or travoprost eye drops.
IOP lowering in both implant cohorts was on par with the drop cohort, Michael H. Goldstein, MD, MBA, said at Glaucoma 360: New Horizons Forum. However, patients in both OTX-TIC cohorts experienced the lowering effect (Read more...)

Full Story →